Lachlan Brown
Stock Analyst at William Blair
(1.83)
# 3,234
Out of 5,065 analysts
10
Total ratings
37.5%
Success rate
5.71%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $170.49 | +17.31% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $38.91 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $7.01 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $12.24 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $388.36 | +54.50% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $300.58 | +16.44% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $19.61 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $81.49 | +10.45% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $81.11 | +171.24% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $170.49
Upside: +17.31%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $38.91
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.01
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.24
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $388.36
Upside: +54.50%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $300.58
Upside: +16.44%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $19.61
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $81.49
Upside: +10.45%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $81.11
Upside: +171.24%